Compass therapeutics announces first patient dosed in the phase 1b ctx-471 combination trial with keytruda® (pembrolizumab)

Boston, dec. 01, 2022 (globe newswire) -- compass therapeutics, inc. (“compass”; nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in the phase 1b study of ctx-471 in combination with keytruda®, merck's anti-pd-1 therapy, in patients with advanced solid tumors.
CMPX Ratings Summary
CMPX Quant Ranking